86t kuh Sin kasa da kasa Pharmaceutical Materials Pharmaceutical Pharmaceutical Materials/Matsakaici/Marufi/Kayan Baje kolin (API China a takaice)

Mai shiryawa: Reed Sinopharm Exhibition Co., Ltd.

Lokacin nuni: Mayu 26-28, 2021

Wuri: Kamfanin Baje kolin Kaya da Fitarwa na China (Guangzhou)

Ma'aunin nuni: 60,000 murabba'in mita

Masu baje kolin: 1500+

Lambar masu sauraro: 60000+

Mu,Changzhou Pharmaceutiacl Factorymallakin Shanghai Pharma.,zai halartaYa Sin Import and Export Fair Complex (Guangzhou)da 10.2M15 don tBaje kolin kayayyakin harhada magunguna na kasa da kasa karo na 86/Matsakaici/Marufi/Kayan aiki (API China a takaice)

A cikin shekarun baya-bayan nan, kasata ta yi nasarar fitar da wasu tsare-tsare don karfafawa da tallafawa ci gaban masana'antar sarrafa kwayoyin halitta. A cikin wannan mahallin, masana'antar biopharmaceutical kuma ta fara shiga wani mataki na haɓaka cikin sauri, kuma ya nuna ƙarfin haɓaka mai ƙarfi. A halin yanzu, haɓakar kasuwancinta ya fara sannu a hankali fiye da yanayin kasuwar magunguna. Rahoton na Frost & Sullivan ya ce, a shekarar 2019, kasuwar hada magunguna ta kasar Sin ta kai yuan biliyan 317.2. Tare da karuwar araha, haɓakar yawan majinyata da faɗaɗa ɗaukar inshorar likitanci, ana sa ran kasuwar maganin ƙwayoyin cuta za ta kai yuan biliyan 464.4 a shekarar 2021.

Bayan haka, a cikin fuskantar manyan tsammanin kasuwa, menene manyan hanyoyin saka hannun jari a cikin masana'antar biopharmaceutical da suka cancanci kulawa a cikin 2021? A cewar masana'antar, bisa la'akari da koma baya na bangaren harhada magunguna, ana ba da shawarar kula da manyan layukan saka hannun jari guda uku a karkashin yanayin haɓaka masana'antu gabaɗaya.:

一.Kamfanoni masu inganci masu inganci tare da gasa ta duniya

Magunguna ya kasance masana'antar fitowar rana tare da ci gaba mai ƙarfi. Koyaya, a ƙarƙashin bayanin cewa masana'antar harhada magunguna suna shiga cikin haɓaka mai inganci kuma masana'antar tana haɓaka sauye-sauyen ta, haɓaka sabbin magunguna ta kamfanonin harhada magunguna shine mabuɗin don warware matsalolin da ba a cika buƙatun asibiti ba, dawwama da kasancewa gasa. 

A halin yanzu, ta fuskar duniya, manyan manyan kamfanonin harhada magunguna duk sababbin kamfanonin magunguna ne. Misali, darajar kasuwar Johnson & Johnson mai magunguna da kayan aiki, ta kai dalar Amurka biliyan 374.5, kuma darajar kasuwan manyan kamfanonin harhada magunguna irin su Roche da Pfizer su ma sun haura dalar Amurka biliyan 100; amma a matsayin Teva Pharmaceuticals, daya daga cikin manyan kamfanonin magunguna na duniya, yana da darajar kasuwa ta dala biliyan 12.3 kacal. Za a iya gani daga sama cewa ƙirƙira ta zama ƙaƙƙarfan ƙarfi don ingantacciyar ci gaban masana'antu da masana'antu.

Yana da kyau a lura cewa idan muna son samun ƙarin kasuwanni, bai isa mu dogara ga kasuwar cikin gida kaɗai ba. Ta hanyar tura magungunan gasa na kasa da kasa zuwa ketare da kuma shiga gasar a kasuwannin duniya tare da karin sarari za mu iya samun damar samun mafi kyawun dawowa. . Don haka, masana'antar gabaɗaya ta yi imanin cewa kamfanoni masu inganci masu inganci tare da gasa a duniya suna da ƙarin damar ci gaba. Ana ba da shawarar kula da sabbin kamfanonin harhada magunguna waɗanda suka kafa tashoshi na tallace-tallace kai tsaye na ketare.

二.Sashin masu cin gajiyar abubuwan da suka shafi DRGs

A cikin 2021, ainihin biyan DRGs zai fara, wanda zai yi tasiri mai zurfi akan ganewar asali da magani na asibiti, kuɗaɗen kula da inshorar likita, da sauransu. Misali, da zarar an aiwatar da DRGs, asibitoci za, ba tare da la'akari da tsada ba, ƙoƙarin iyakance yin amfani da wasu magunguna masu tsada, har ma da magungunan bincike na asali, kamfanonin harhada magunguna da suka dace za su fuskanci mummunar lalacewa idan ba su canza a cikin lokaci ba.

Koyaya, kodayake wasu magunguna da kamfanoni za su fuskanci ƙalubale sosai. Koyaya, masana'antar ta annabta cewa nau'ikan magungunan da ke da halayen amfani mai ƙarfi, magungunan gaggawa, jiyya na ƙarshen zamani da magungunan marasa lafiya ba za su iya shafar ba, kuma a ƙarƙashin ƙimar fa'ida, zai haɓaka haɓaka ƙimar shigar ICL da shigo da kaya. maye gurbin masana'antar IVD. Bugu da ƙari, ainihin albarkatu na sama (kayan kayan aiki da kayan aiki, APIs masu haƙƙin mallaka) na iya amfana daga wannan. Ana ba da shawarar kula da: WuXi Biologics, Tofflon, Kailai Ying da sauran kamfanoni.

三.Filin fitar da magunguna na R&D mai wadata sosai

Karkashin tasirin abubuwa kamar karuwar saka hannun jari na R&D na magunguna na duniya da ingantattun manufofin cikin gida, yarjejeniya ce a cikin masana'antar cewa kasuwar sabis na fitar da magunguna ta R&D (watau CXO), wani muhimmin bangare na sarkar masana'antar magunguna, za ta kasance mai inganci. a fili fa'ida.

Masu binciken masana'antu sun yi imanin cewa masu farawa yanzu sannu a hankali sun zama babban karfi a cikin bincike da haɓaka sabbin magunguna a cikin masana'antar ilimin halittu. Koyaya, saboda ƙarancin hazaka, kuɗi, da sarari, masu farawa galibi suna daidaita ma'aikata kuma suna bin babban inganci da ƙarancin farashi. Saboda haka, sun dogara ga kamfanonin CXO. Yana son zama mafi girma. An fahimci cewa, wani kamfani na CMO da aka jera ya bayyana cewa, saboda waɗannan dalilai na sama, yawan kamfanonin da suka fara samar da magunguna na zamani a cikin ayyukan kamfanonin CXO ya karu a hankali a cikin 'yan shekarun nan, kuma yana zama muhimmiyar hanyar taimakawa. zuwa haɓakar kudaden shiga da ribar kamfanin CXO.